Carregant...

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study

Tanespimycin, a heat shock protein 90 (HSP90) inhibitor, induces apoptosis in drug-sensitive and -resistant MM cell lines and in tumour cells from patients with relapsed MM. In this phase 1 dose-escalation study, the safety, plasma pharmacokinetics, and biological/antitumour activity of tanespimycin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Richardson, Paul G., Chanan-Khan, Asher A., Alsina, Melissa, Albitar, Maher, Berman, David, Messina, Marianne, Mitsiades, Constantine S., Anderson, Kenneth C.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3126095/
https://ncbi.nlm.nih.gov/pubmed/20618337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08265.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!